U.S. markets open in 4 hours 14 minutes

Terns Pharmaceuticals, Inc. (TERN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
15.25-0.35 (-2.24%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Performance Outlook
Previous Close15.60
Open15.61
Bid0.00 x 1400
Ask0.00 x 800
Day's Range15.25 - 15.95
52 Week Range14.36 - 28.36
Volume214,300
Avg. Volume91,649
Market Cap382.976M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Terns Shares Drop After Mixed Results From Mid-Stage NASH Trial With FXR Agonist
    Benzinga

    Terns Shares Drop After Mixed Results From Mid-Stage NASH Trial With FXR Agonist

    Terns Pharmaceuticals Inc (NASDAQ: TERN) reported top-line results from the Phase 2a LIFT trial of TERN-101, a liver-distributed farnesoid X receptor (FXR) agonist for the treatment of patients with non-alcoholic steatohepatitis (NASH). TERN-101 was generally well-tolerated in the trial with a similar incidence of adverse events across treatment groups. All treatment-related adverse events were mild/moderate with no apparent dose relationship. There were no treatment-related serious adverse even

  • Terns Reports Positive Top-line Results from Phase 2a LIFT Study of FXR Agonist TERN-101 in Patients with NASH
    GlobeNewswire

    Terns Reports Positive Top-line Results from Phase 2a LIFT Study of FXR Agonist TERN-101 in Patients with NASH

    First FXR agonist trial to demonstrate no discontinuations due to AEs, including pruritus, and both a differentiated pruritus and lipid profile in patients with NASH First 12-week controlled trial in patients with NASH to show significant improvements in corrected T1 (cT1), an imaging marker of liver inflammation and fibrosis linked to clinical outcomes Terns plans to initiate first NASH trial of an FXR agonist (TERN-101) in combination with a THR-β agonist (TERN-501) in 1H22 Company to host con

  • Terns Pharmaceuticals to Host Conference Call to Discuss Top-line Results from Phase 2a LIFT Study of TERN-101 for Treatment of NASH
    GlobeNewswire

    Terns Pharmaceuticals to Host Conference Call to Discuss Top-line Results from Phase 2a LIFT Study of TERN-101 for Treatment of NASH

    FOSTER CITY, Calif., June 13, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, announced that the Company will host a conference call and live webcast on Monday, June 14, 2021 at 8:30 a.m. ET (5:30 a.m. PT) to discuss new top-lin